Argos Therapeutics Announces CEO Jeff Abbey Elected to NCBIO Board of Directors
October 26, 2016 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics to Host Investor Day on Wednesday, December 7, 2016
October 19, 2016 08:00 ET
|
Argos Therapeutics Inc.
Event to be held at NASDAQ MarketSite in New York City from 8:00-11:00 a.m. Eastern Time. Immunology and kidney cancer experts to review the company’s individualized immunotherapies based on the...
Argos Therapeutics to Participate in 2016 BIO Investor Forum
October 14, 2016 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics to Participate in 2016 Cell & Gene Meeting on the Mesa
October 03, 2016 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly individualized...
Argos Therapeutics to Participate in 23rd Annual NewsMakers in the Biotech Industry Conference
September 01, 2016 16:05 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly...
Argos Therapeutics Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
August 10, 2016 16:05 ET
|
Argos Therapeutics Inc.
- Independent Data Monitoring Committee Recommended Continuation of Phase 3 ADAPT Trial of AGS-003 in Metastatic Renal Cell Carcinoma - - Closed on $29.8 million Second Tranche of March 2016...
Argos Therapeutics to Host Second Quarter 2016 Financial Results Conference Call on Wednesday, August 10, 2016
August 04, 2016 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly individualized...
Argos Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock and Warrants
July 28, 2016 09:22 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., July 28, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
July 27, 2016 16:06 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., July 27, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics Announces First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIV
July 14, 2016 08:30 ET
|
Argos Therapeutics Inc.
The investigator-initiated Phase 2 trial is designed to evaluate the virologic impact of the combination of the latency-reversing drug, vorinostat, and AGS-004, the company’s investigational...